Heart failure (HF) affects more than 64 million people worldwide and remains one of the leading causes of hospitalization and mortality. Despite advances in treatment, many patients are still diagnosed at advanced stages, making early risk assessment and accurate prognosis increasingly important.
Cardiac biomarker sST2 (soluble suppression of tumorigenicity 2) has emerged as a valuable indicator for assessing myocardial fibrosis, ventricular remodeling, and heart failure prognosis. Unlike traditional biomarkers, sST2 provides prognostic information that is less affected by age, body mass index, renal function, or atrial fibrillation, making it a highly reliable complement to natriuretic peptides such as BNP and NT-proBNP.
As the clinical demand for precision cardiovascular diagnostics continues to grow, developing highly sensitive and reliable ST2 assays begins with one essential factor: high-quality IVD raw materials.
Cardiac biomarkers ST2 Is Recommended by Leading Guidelines
sST2 is now recognized independent marker for heart failure risk stratification and long-term prognosis, offering incremental value beyond BNP/NT-proBNP.
—2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure
sST2 is included as a specific biomarker of myocardial fibrosis, and the combined testing of BNP and sST2 is recommended for long-term risk prediction in chronic heart failure.
— 2021 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure
Cnpair Cardiac biomarkers ST2 Performance
Validated on chemiluminescence (AE) platform, Cnpair’s ST2 antibodies demonstrated ＞98% correlation with leading international commercial reagents. Compatible with CLIA, ELISA, and LF, they offer broad flexibility for diverse diagnostic systems and applications.
At Cnpair, we provide high-quality ST2 antibodies and antigens, to support the development of high-performance diagnostic assays. Our ST2 raw materials deliver high sensitivity, excellent specificity, and consistent batch-to-batch performance, enabling reliable assay development for early heart failure detection and precise clinical evaluation.
Partner with Cnpair
At Cnpair, we are committed to providing high-quality IVD raw materials that enable accurate, reliable, and reproducible diagnostic testing.
Our comprehensive portfolio of antibodies, antigens, recombinant proteins, and diagnostic solutions supports assay development across cardiovascular disease, infectious disease, oncology, autoimmune disease, and other clinical applications.
Whether you are developing a new ST2 assay or optimizing an existing product, our experienced technical team is ready to support your project from research through commercialization.
Reliable raw materials build reliable diagnostics—empowering earlier detection, more accurate clinical decisions, and better patient outcomes.
